Probiotics and GLP-1 Medicines: What We Know, and What We Don't

If your digestion has gone strange since you started a GLP-1 medicine, you’re in very well-documented company. Here’s what 101 randomized trials — and the drug labels themselves — actually say.

Photo: RDNE Stock project/ https://www.pexels.com

What these medicines do to digestion

GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide, exenatide — copy a hormone your gut already makes after you eat. Tirzepatide (Mounjaro, Zepbound) is a close cousin. Its label calls it “a GIP receptor and GLP-1 receptor agonist”³, meaning it works on two receptors instead of one.

They do three things that matter here. They help regulate blood sugar. They act on appetite. And they slow your stomach down — which is where most of this article comes from. The labels are blunt about it: “Semaglutide delays gastric emptying,” says one². “Tirzepatide delays gastric emptying,” says the other³. Food sits longer. You feel full sooner. And the slowdown carries on down the line.

How common is this, really?

Common enough that it’s been measured properly. A 2026 meta-analysis pooled 101 randomized controlled trials with 57,684 participants, 41,443 of whom actually received one of five GLP-1 medicines¹. Compared with placebo, those people were:

• 2.9× as likely to report nausea — far and away the most common one, at 22.8% of participants
• 3.6× as likely to report vomiting (9.1%)
• 2.4× as likely to report constipation (7.4%)
• just under twice as likely to report diarrhea — a risk ratio of 1.97 (13%)

Those are averages across every trial and every dose. At the higher weight-management doses, the label figures run higher: nausea in 44% of people on semaglutide 2.4 mg against 16% on placebo, and constipation in 24% against 11%². The drugs also aren’t interchangeable — tirzepatide carried the highest risk for nausea and diarrhea, semaglutide for vomiting and constipation¹. That may be why your experience looks nothing like your friend’s.

And the other side of all those percentages: constipation at 24% means three in four people didn’t report it at all.

“Regardless of the GLP-1 RAs used, it is apparent that GI AEs are significant and highly prevalent.”¹

Why the first few weeks are the worst of it

Both labels tell prescribers to start low and step the dose up slowly, and both say exactly why: to “reduce the risk of gastrointestinal adverse reactions”^2,3. The tirzepatide label goes further and explains the mechanism — the delay in stomach emptying “is largest after the first dose and this effect diminishes over time”³. Your stomach adapts. It just doesn’t adapt on your schedule. Most people who stopped treatment because of side effects did so “during the first few months”³.

Here’s something worth knowing. The semaglutide label hands prescribers a lever: “If patients do not tolerate a dose during dosage escalation, consider delaying dosage escalation for 4 weeks”². That’s a conversation to have with whoever prescribed it, rather than quietly white-knuckling through.

Photo: Liza Summer/ https://www.pexels.com

The ordinary things that actually help

None of this is dramatic. It’s also, for most people, the part that does the most work. A 2026 review of eating well while on anti-obesity medication is where most of it comes from⁴.

• Fluids — more than you think. When your appetite drops, what you drink quietly drops with it. The review suggests at least 2 liters a day, and offers one genuinely useful trick: keep drinks at least an hour either side of meals, because filling a slow stomach with liquid at mealtimes just makes the fullness worse.
• Fiber, raised gently. Go up gradually and take the fluids up with it. The review puts a neat condition on it — fiber-rich food helps “provided that the fiber is well tolerated.” If more fiber makes the bloating worse, and for some people it does, that’s information, not failure. A lower-residue diet can suit some people better “particularly during the initiation or dose escalation phases.”
• Smaller meals, eaten slower. When your stomach is emptying at half speed, the plateful you managed six months ago isn’t the plateful you manage now. Stop when you stop being hungry, not when the plate is empty.
• Movement, of the unglamorous kind. Regular activity may help keep things moving. The review suggests starting with short, low-intensity walks and light resistance work and building from there. On the muscle that tends to come off alongside fat during quick weight loss, it points to adequate protein — roughly 1.2 to 1.6 g per kg of body weight a day — combined with resistance training. Worth raising with your care team.

Photo: Gustavo Fring/ https://www.pexels.com

That’s the medicine half. Real effects, well counted, usually worst early, mostly manageable with fluids, gentler meals and patience — plus a short list of things that deserve a phone call rather than a wait-and-see.

What actually makes a probiotic worth taking

The real definition is tighter than the marketing. Internationally, a probiotic is “live microorganisms which when administered in adequate amounts confer a health benefit on the host”⁵. Two phrases carry the weight there. Adequate amounts means a defined dose. Confer a health benefit means it has to have been shown to do something. A jar of live bacteria nobody has studied is a jar of live bacteria.

And the big number on the front of the bottle isn’t the answer. The NIH Office of Dietary Supplements is refreshingly direct: “Higher CFU counts alone do not necessarily mean that the product has greater health benefits. A product’s health benefits, if any, are determined by both the specific microorganisms (or strains) it contains and the number of CFUs”⁶. Its guidance for clinicians makes the same point — “[b]ecause the effects of probiotics can be specific to certain probiotic strains, recommendations for their use in the clinic need to be strain-specific”⁷. The biggest number on the shelf isn’t automatically the best product on the shelf. It’s just the biggest number.

What the research shows about regularity

The most useful recent evidence is a 2024 meta-analysis of 17 studies covering 1,256 adults⁸. Probiotic-containing products increased stool frequency by 0.93 bowel movements a week against placebo (95% CI 0.47 to 1.40), with smaller improvements in stool consistency and symptom scores. That’s a real effect, and a modest one. The reviewers graded it “low” quality for stool frequency and “very low” for the other two, and wrote that the evidence “ought to be used with caution”⁸. We’d rather give you that number than a rounder one.

Where Flourish comes in

Flourish is a living liquid probiotic, fermented and bottled in Sioux Center, Iowa. It carries eleven organisms rather than one, in a fermented liquid base instead of a capsule or a powder. You take it by the capful.

Here’s what we’ll say about it, plainly. Flourish helps maintain healthy intestinal flora. It helps maintain regularity. It can be used for the relief of occasional constipation. It fits into an ordinary daily routine, or into simply paying more attention to your gut than you used to.*

And here’s what we won’t say. Those trials above used named, individually studied strains, and ours aren’t those strains. We haven’t run that trial on Flourish itself, and we’re not going to imply we have. What we can tell you is that Flourish is built along the lines the evidence points to — a range of organisms rather than one headline strain, at a daily amount rather than a number chosen to look impressive on a label.

One honest limit. Occasional constipation isn’t the same thing as chronic or persistent constipation. Flourish isn’t intended for chronic constipation, which can be a sign of something underlying and should be looked at by a healthcare professional. If your symptoms are persistent, severe, or come with pain, vomiting, blood in the stool or unexplained weight loss, that’s a reason to be seen — not a reason to try another supplement.

The 30-Day Flourish Challenge

Here’s the thing about probiotics: a scattered week tells you nothing. You take it Monday, forget Tuesday and Wednesday, remember on Thursday, run out of patience by the weekend — and then conclude it didn’t work. That isn’t a fair test. Not of Flourish, not of anything.

So we’d rather you did it properly. Thirty days. One capful a day. That’s the whole challenge. There’s nothing to sign up for and nothing to post.

Why thirty? Partly because a bottle is roughly that. Mostly because thirty days is long enough for something to stop being a novelty and start being a habit — and a habit is the only state in which you can honestly tell whether something suits you.

How to actually get through it

• Pick a time you won’t have to remember. Tie it to something you already do without thinking — the kettle going on, the dinner plates coming out.
• Keep it in the fridge door, not the back of a shelf. Out of sight is far and away the most common reason a bottle never gets finished.
• Write two notes. One in week one, one in week four — how you’re feeling, how things are moving. Not a spreadsheet, just a note on your phone. Memory is unreliable about this sort of thing, and it flatters whatever you already believe.
• Don’t change five things at once. If you start Flourish, a fiber supplement and a walking routine on the same Monday, you’ll learn nothing about any of them.

What we’re not promising

Anything about day thirty. We don’t know what your thirty days will look like, and anyone who tells you they do is guessing. What we can point you to is what the research says about probiotics and regularity — which is a few paragraphs up, and which is modest.

The challenge isn’t a promise. It’s just a fair test.

Flourish Original is available at entegrohealth.com if you want to give it thirty days.

One last thing on safety, because it’s reasonable to ask. Probiotics have been studied for tolerability in large randomized trials. A 2025 Cochrane review of adults and children taking antibiotics pooled adverse-event data from 37 trials and 11,911 participants and found no excess of adverse events in the probiotic groups — if anything slightly fewer (10.9% against 12.2%; RR 0.86, 95% CI 0.72 to 1.01)⁹.

The short version

We could have told you probiotics fix constipation. The honest number is about one extra bowel movement a week, on evidence the reviewers themselves called low quality — and where that effect turned up was multi-strain products at ordinary doses, not single strains at spectacular ones.

That’s the kind of product Flourish is built to be. If that’s the kind of claim you’d rather be sold, we’d be glad to have you for thirty days.

Sources

1. Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026). Exploring the rates of gastrointestinal adverse effects among five GLP-1 receptor agonists: a systematic review and meta-analysis of randomized controlled trials. Endocrine, 91(1), 23 — 101 randomized controlled trials, 57,684 participants of whom 41,443 received a GLP-1 receptor agonist; nausea RR 2.90, vomiting RR 3.60, constipation RR 2.41, diarrhea RR 1.97. Source
2. WEGOVY (semaglutide) injection and tablets — Prescribing Information. Novo Nordisk, via DailyMed — “Semaglutide delays gastric emptying”; dosage escalation “to reduce the risk of gastrointestinal adverse reactions”; adverse reaction tables; cholelithiasis 1.6% versus 0.7%; post-marketing reports of ileus, intestinal obstruction and severe constipation including fecal impaction. Source
3. ZEPBOUND (tirzepatide) injection — Prescribing Information. Eli Lilly and Company, via DailyMed — “Tirzepatide is a GIP receptor and GLP-1 receptor agonist”; “The delay is largest after the first dose and this effect diminishes over time”; cholecystitis 0.7% versus 0.2%; post-marketing reports. Source
4. Pardali, E. C., Gkouskou, K. K., Cholevas, C., Poulimeneas, D., Tsiroukidou, K., Goulis, D. G., & Grammatikopoulou, M. G. (2026). New drugs on the block: dietary management and nutritional considerations during the use of anti-obesity medication. Nutrients, 18(6), 962 — at least 2 L daily fluid; drinks at least one hour either side of meals; fiber “provided that the fiber is well tolerated”; low-residue diet during initiation and escalation; protein 1.2–1.6 g/kg combined with resistance training. Source
5. Hill, C., Guarner, F., Reid, G., Gibson, G. R., Merenstein, D. J., Pot, B., et al. (2014). Expert consensus document: The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology, 11(8), 506–514. Source
6. National Institutes of Health, Office of Dietary Supplements. Probiotics: Fact Sheet for Consumers — “Higher CFU counts alone do not necessarily mean that the product has greater health benefits.” Source
7. National Institutes of Health, Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals — “Because the effects of probiotics can be specific to certain probiotic strains, recommendations for their use in the clinic need to be strain-specific.” Source
8. Ding, F., Hu, M., Ding, Y., Meng, Y., & Zhao, Y. (2024). Efficacy in bowel movement and change of gut microbiota on adult functional constipation patients treated with probiotics-containing products: a systematic review and meta-analysis. BMJ Open, 14(1), e074557 — 17 studies, 1,256 participants; stool frequency WMD 0.93/week (GRADE low), consistency and PAC-SYM (GRADE very low); multi-strain WMD 1.38; Lactobacillus-only and Bifidobacterium-only subgroups non-significant; synbiotics WMD 1.25 versus probiotics alone 0.83; dose 0.1–30×10⁹ CFU/day “had non-significant influence.” Source
9. Esmaeilinezhad, Z., Ghosh, N. R., Walsh, C. M., Steen, J. P., Burgman, A. M., Mertz, D., & Johnston, B. C. (2025). Probiotics for the prevention of Clostridioides difficile-associated diarrhea in adults and children. Cochrane Database of Systematic Reviews, 9(9), CD006095 — adverse-event analysis pooled 37 trials and 11,911 participants; 10.9% versus 12.2%, RR 0.86 (95% CI 0.72 to 1.01), moderate-certainty evidence. Source